SLGL News and Press, Sol-Gel Technologies Ltd. From 02/14/20

Thinly traded Sol-Gel Technologies (NASDAQ: SLGL ) slumps  23%  premarket on light volume in response to its public offering of ~2.1M ordinary shares and three-year warrants to purchase up to an aggregate of ~1.7M ordinary shares at a combined price of $11.00 per share and accomp...

NESS ZIONA, Israel, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for...

Successful topline results, strengthens Epsolay’s long-term safety and tolerability profile in the treatment of papulopustular rosacea Results pave the way for NDA submission in the second quarter of 2020 NESS ZIONNA, Israel, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technol...

Gainers : Rexahn Pharmaceuticals (NASDAQ: REXN )  +85% . More news on: Rexahn Pharmaceuticals, Inc., Sprint Corporation, Genprex, Inc., Stocks on the move, , Read more ...

Today, we will see why Sol-Gel Technologies ( SLGL ) is a promising small-cap dermatology pick for 2020. Company overview Sol-Gel Technologies Ltd. is a clinical-stage dermatology company focused on becoming leaders in the treatment of acne and rosacea. Sol-Gel Technologies has two inves...

NESS ZIONA, Israel, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for ...

Most investors have probably never heard of Sol-Gel Technologies (NASDAQ: SLGL) . That wouldn't be too surprising. It's a small Israeli-based dermatology company with a pretty limited pipeline. The pharma stock tumbled in 2018 to drag the company's market valuation well below $100 million a...

NESS ZIONA, Israel, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) today announced the presentation of results from the Company’s Phase 3 trials for its candidates Epsolay® (microencapsulated be...

Conference call with Sol-Gel management and U.S. key opinion leader today at 8:00 a.m. Eastern time NESS ZIONA, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) will host a conference call today to discuss results from two Phase 3 clinical trials fo...

Sol-Gel Technologies (SLGL) had announced that it achieved positive results from its two pivotal studies using Twyneo to treat patients with acne vulgaris. The company prides itself on its drug delivery technology, microencapsulation, which is able to deliver topical treatments for these p...